291ORibociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs). (23rd October 2018) - Harbeck, N; Villanueva, R; Franke, F; Babu, G; Wheatley-Price, P; Im, Y-H; Altundag, K; Lanoue, B; Alam, J; Chandiwana, D; Colleoni, M